CTOs on the Move

AstraZeneca

www.astrazeneca.com

 
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.astrazeneca.com
  • 1800 Concord Pike P.O. Box 15437
    Wilmington, DE USA 19850
  • Phone: 302.886.3000

Executives

Name Title Contact Details
Sean Connolly
Chief Technology Officer, Evinova Profile
Brooks Cucuel
Senior Director, Security and Business Resilience Profile

Similar Companies

Lannett Company

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications.

Koneksa Health

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries.

Accord Healthcare

Accord Healthcare is a global provider of generic and specialty pharmaceuticals. Our focus on a rapidly expanding portfolio of affordable generic…

Clinical RM

Clinical RM is a Hinckley, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.